Clonal competition with alternating dominance in multiple myeloma

Jonathan J. Keats, Marta Chesi, Jan B. Egan, Victoria M. Garbitt, Stephen E. Palmer, Esteban D Braggio, Scott Van Wier, Patrick R. Blackburn, Angela S. Baker, Angela Dispenzieri, Shaji K Kumar, S Vincent Rajkumar, John D. Carpten, Michael Barrett, Rafael Fonseca, Alexander Keith Stewart, Peter Leif Bergsagel

Research output: Contribution to journalArticle

384 Citations (Scopus)

Abstract

Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.

Original languageEnglish (US)
Pages (from-to)1067-1076
Number of pages10
JournalBlood
Volume120
Issue number5
DOIs
StatePublished - Aug 2 2012

Fingerprint

Multiple Myeloma
Tumors
Clone Cells
Genes
Neoplasms
Genome
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Clonal competition with alternating dominance in multiple myeloma. / Keats, Jonathan J.; Chesi, Marta; Egan, Jan B.; Garbitt, Victoria M.; Palmer, Stephen E.; Braggio, Esteban D; Van Wier, Scott; Blackburn, Patrick R.; Baker, Angela S.; Dispenzieri, Angela; Kumar, Shaji K; Rajkumar, S Vincent; Carpten, John D.; Barrett, Michael; Fonseca, Rafael; Stewart, Alexander Keith; Bergsagel, Peter Leif.

In: Blood, Vol. 120, No. 5, 02.08.2012, p. 1067-1076.

Research output: Contribution to journalArticle

Keats, Jonathan J. ; Chesi, Marta ; Egan, Jan B. ; Garbitt, Victoria M. ; Palmer, Stephen E. ; Braggio, Esteban D ; Van Wier, Scott ; Blackburn, Patrick R. ; Baker, Angela S. ; Dispenzieri, Angela ; Kumar, Shaji K ; Rajkumar, S Vincent ; Carpten, John D. ; Barrett, Michael ; Fonseca, Rafael ; Stewart, Alexander Keith ; Bergsagel, Peter Leif. / Clonal competition with alternating dominance in multiple myeloma. In: Blood. 2012 ; Vol. 120, No. 5. pp. 1067-1076.
@article{40a8f280b6fa4a0cb9eb915f8081d9c6,
title = "Clonal competition with alternating dominance in multiple myeloma",
abstract = "Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.",
author = "Keats, {Jonathan J.} and Marta Chesi and Egan, {Jan B.} and Garbitt, {Victoria M.} and Palmer, {Stephen E.} and Braggio, {Esteban D} and {Van Wier}, Scott and Blackburn, {Patrick R.} and Baker, {Angela S.} and Angela Dispenzieri and Kumar, {Shaji K} and Rajkumar, {S Vincent} and Carpten, {John D.} and Michael Barrett and Rafael Fonseca and Stewart, {Alexander Keith} and Bergsagel, {Peter Leif}",
year = "2012",
month = "8",
day = "2",
doi = "10.1182/blood-2012-01-405985",
language = "English (US)",
volume = "120",
pages = "1067--1076",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Clonal competition with alternating dominance in multiple myeloma

AU - Keats, Jonathan J.

AU - Chesi, Marta

AU - Egan, Jan B.

AU - Garbitt, Victoria M.

AU - Palmer, Stephen E.

AU - Braggio, Esteban D

AU - Van Wier, Scott

AU - Blackburn, Patrick R.

AU - Baker, Angela S.

AU - Dispenzieri, Angela

AU - Kumar, Shaji K

AU - Rajkumar, S Vincent

AU - Carpten, John D.

AU - Barrett, Michael

AU - Fonseca, Rafael

AU - Stewart, Alexander Keith

AU - Bergsagel, Peter Leif

PY - 2012/8/2

Y1 - 2012/8/2

N2 - Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.

AB - Emerging evidence indicates that tumors can follow several evolutionary paths over a patient's disease course. With the use of serial genomic analysis of samples collected at different points during the disease course of 28 patients with multiple myeloma, we found that the genomes of standard-risk patients show few changes over time, whereas those of cytogenetically high-risk patients show significantly more changes over time. The results indicate the existence of 3 temporal tumor types, which can either be genetically stable, linearly evolving, or heterogeneous clonal mixtures with shifting predominant clones. A detailed analysis of one high-risk patient sampled at 7 time points over the entire disease course identified 2 competing subclones that alternate in a back and forth manner for dominance with therapy until one clone underwent a dramatic linear evolution. With the use of the Vk*MYC genetically engineered mouse model of myeloma we modeled this competition between subclones for predominance occurring spontaneously and with therapeutic selection.

UR - http://www.scopus.com/inward/record.url?scp=84861532638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861532638&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-01-405985

DO - 10.1182/blood-2012-01-405985

M3 - Article

C2 - 22498740

AN - SCOPUS:84861532638

VL - 120

SP - 1067

EP - 1076

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -